MedTrace Logo

Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial

NCT05308979 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 116

Last updated 2026-02-25

Study results available
· View outcomes & findings →

Summary

Patients with either overactive bladder (OAB) or urgency urinary incontinence (UUI) with be randomized (like a flip of a coin) to receive 100 units of bladder Botox® at either one injection site or ten injection sites. Efficacy and patient satisfaction will be measured by questionnaires.

Conditions

  • Overactive Bladder
  • Urinary Urge Incontinence
  • Overactive Bladder Syndrome
  • Urinary Incontinence, Urge
  • Urge Incontinence
  • Urinary Urgency
  • Urinary Frequency

Interventions

DRUG

OnabotulinumtoxinA 100 UNT [Botox]

Intradetrusor (Bladder) Botox Injection at 1 vs 10 injection sites

Sponsors & Collaborators

  • Kaiser Permanente

    collaborator OTHER

  • St. Joseph Hospital of Orange

    collaborator OTHER

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Carly Crowder, MD · UC Irvine

  • Taylor Brueseke, MD · UC Irvine

  • Felicia Lane, MD · UC Irvine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-12-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05308979 on ClinicalTrials.gov